aTyr Pharma
ATYR
23 hedge funds and large institutions have $18.6M invested in aTyr Pharma in 2020 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 8 increasing their positions, 2 reducing their positions, and 4 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 2
159% more capital inflows, than outflows
Capital inflows: $1.06M | Capital outflows: $410K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.86% less ownership
Funds ownership: 59.86% → 58% (-1.9%)
4% less funds holding
Funds holding: 24 → 23 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Advisers
New York
|
+$358K |
| 2 |
Renaissance Technologies
New York
|
+$175K |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
+$109K |
| 4 |
Millennium Management
New York
|
+$93.5K |
| 5 |
Two Sigma Investments
New York
|
+$83.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$158K |
| 2 |
JP Morgan Private Wealth Advisors
San Francisco,
California
|
-$100K |
| 3 |
Oppenheimer & Co
New York
|
-$81K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$53K |
| 5 |
Morgan Stanley
New York
|
-$10K |
ATYR Hedge Fund Activity: Q3 2020 in Review
23 of the 4,972 institutional investors tracked by Wall St. Rank reported a position in aTyr Pharma (ATYR) for Q3 2020, worth a combined $18.6M — down 25% from $24.9M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of ATYR and 3 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 8 added.
The largest buyer was Two Sigma Advisers, adding an estimated $358K. The largest seller was UBS Group, cutting an estimated $158K.
- 23 institutional investors held aTyr Pharma (ATYR) as of Q3 2020, down from 24 in Q2 2020.
- Funds reported $18.6M of aTyr Pharma stock for Q3 2020, down 25% quarter-over-quarter.
- 3 funds opened new aTyr Pharma positions in Q3 2020 and 4 closed out, a net change of -1 holder.
- The largest aTyr Pharma buyer in Q3 2020 was Two Sigma Advisers, an estimated $358K added.
- The largest aTyr Pharma seller in Q3 2020 was UBS Group, an estimated $158K sold.
Based on aggregated 13F filings for Q3 2020.